Nektar Therapeutics (NASDAQ: NKTR) is -21.24% lower on its value in year-to-date trading and has touched a low of $13.63 and a high of $28.60 in the current 52-week trading range. The NKTR stock was last observed hovering at around $17.94 in the last trading session, with the day’s loss setting it -0.94% off its average median price target of $26.00 for the next 12 months. It is also 78.75% off the consensus price target high of $80.00 offered by 15 analysts, but current levels are 10.53% higher than the price target low of $19.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $17.00, the stock is -4.82% and -1.25% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.9 million and changing -5.24% at the moment leaves the stock -13.01% off its SMA200. NKTR registered -18.89% loss for a year compared to 6-month loss of -27.72%. The firm has a 50-day simple moving average (SMA 50) of $17.48 and a 200-day simple moving average (SMA200) of $19.35.
The stock witnessed a 3.22% gain in the last 1 month and extending the period to 3 months gives it a 1.74%, and is -8.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.40% over the week and 4.55% over the month.
Nektar Therapeutics (NKTR) has around 723 employees, a market worth around $3.22B and $163.30M in sales. Distance from 52-week low is 24.72% and -40.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-26.60%).
Nektar Therapeutics (NKTR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Nektar Therapeutics (NKTR) is a “Overweight”. 15 analysts offering their recommendations for the stock have an average rating of 2.20, where 6 rate it as a Hold and 0 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Nektar Therapeutics is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.74 with sales reaching $20.63M over the same period.The EPS is expected to shrink by -166.60% this year, but quarterly earnings will post 30.50% year-over-year. Quarterly sales are estimated to shrink -39.10% in year-over-year returns.
Nektar Therapeutics (NKTR) Top Institutional Holders
359 institutions hold shares in Nektar Therapeutics (NKTR), with 1.55M shares held by insiders accounting for 0.87% while institutional investors hold 98.65% of the company’s shares. The shares outstanding are 179.09M, and float is at 177.84M with Short Float at 13.81%. Institutions hold 97.79% of the Float.
The top institutional shareholder in the company is Invesco Ltd. with over 35.69 million shares valued at $592.12 million. The investor’s holdings represent 19.89% of the NKTR Shares outstanding. As of Sep 29, 2020, the second largest holder is FMR, LLC with 19.56 million shares valued at $324.48 million to account for 10.90% of the shares outstanding. The other top investors are Primecap Management Company which holds 18.87 million shares representing 10.52% and valued at over $313.0 million, while Blackrock Inc. holds 10.02% of the shares totaling 17.98 million with a market value of $298.22 million.
Nektar Therapeutics (NKTR) Insider Activity
The most recent transaction is an insider sale by Myriam Curet, the company’s Director. SEC filings show that Myriam Curet sold 1,560 shares of the company’s common stock on Dec 15 at a price of $17.82 per share for a total of $27799.0. Following the sale, the insider now owns 19240.0 shares.
Nektar Therapeutics disclosed in a document filed with the SEC on Nov 23 that Zalevsky Jonathan (Chief R&D Officer) sold a total of 16,380 shares of the company’s common stock. The trade occurred on Nov 23 and was made at $16.40 per share for $0.27 million. Following the transaction, the insider now directly holds 0.25 million shares of the NKTR stock.
Still, SEC filings show that on Nov 16, Zalevsky Jonathan (Chief R&D Officer) disposed off 29,618 shares at an average price of $16.93 for $0.5 million. The insider now directly holds 266,697 shares of Nektar Therapeutics (NKTR).
Nektar Therapeutics (NKTR): Who are the competitors?
The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading -0.79% down over the past 12 months. Pfizer Inc. (PFE) is -0.76% down on the 1-year trading charts. Short interest in the company’s stock has fallen -0.57% from the last report on Nov 12, 2020 to stand at a total of 24.7 million short shares sold with a short interest ratio of 31.12.